Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
737 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Parkinson's Disease - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Parkinson's Disease - Pipeline Review, H2 2014', provides an overview of the Parkinson's Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Parkinson's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Parkinson's Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Parkinson's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Parkinson's Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 9 Parkinson's Disease Overview 10 Therapeutics Development 11 Parkinson's Disease - Therapeutics under Development by Companies 13 Parkinson's Disease - Therapeutics under Investigation by Universities/Institutes 28 Parkinson's Disease - Pipeline Products Glance 32 Parkinson's Disease - Products under Development by Companies 36 Parkinson's Disease - Products under Investigation by Universities/Institutes 53 Parkinson's Disease - Companies Involved in Therapeutics Development 57 Parkinson's Disease - Therapeutics Assessment 227 Drug Profiles 245 Parkinson's Disease - Recent Pipeline Updates 604 Parkinson's Disease - Dormant Projects 689 Parkinson's Disease - Discontinued Products 696 Parkinson's Disease - Product Development Milestones 697 Appendix 704
List of Tables Number of Products under Development for Parkinson's Disease, H2 2014 43 Number of Products under Development for Parkinson's Disease - Comparative Analysis, H2 2014 44 Number of Products under Development by Companies, H2 2014 46 Number of Products under Development by Companies, H2 2014 (Contd..1) 47 Number of Products under Development by Companies, H2 2014 (Contd..2) 48 Number of Products under Development by Companies, H2 2014 (Contd..3) 49 Number of Products under Development by Companies, H2 2014 (Contd..4) 50 Number of Products under Development by Companies, H2 2014 (Contd..5) 51 Number of Products under Development by Companies, H2 2014 (Contd..6) 52 Number of Products under Development by Companies, H2 2014 (Contd..7) 53 Number of Products under Development by Companies, H2 2014 (Contd..8) 54 Number of Products under Development by Companies, H2 2014 (Contd..9) 55 Number of Products under Development by Companies, H2 2014 (Contd..10) 56 Number of Products under Development by Companies, H2 2014 (Contd..11) 57 Number of Products under Development by Companies, H2 2014 (Contd..12) 58 Number of Products under Development by Companies, H2 2014 (Contd..13) 59 Number of Products under Investigation by Universities/Institutes, H2 2014 61 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 62 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 63 Comparative Analysis by Late Stage Development, H2 2014 64 Comparative Analysis by Clinical Stage Development, H2 2014 65 Comparative Analysis by Early Stage Development, H2 2014 66 Comparative Analysis by Unknown Stage Development, H2 2014 67 Products under Development by Companies, H2 2014 68 Products under Development by Companies, H2 2014 (Contd..1) 69 Products under Development by Companies, H2 2014 (Contd..2) 70 Products under Development by Companies, H2 2014 (Contd..3) 71 Products under Development by Companies, H2 2014 (Contd..4) 72 Products under Development by Companies, H2 2014 (Contd..5) 73 Products under Development by Companies, H2 2014 (Contd..6) 74 Products under Development by Companies, H2 2014 (Contd..7) 75 Products under Development by Companies, H2 2014 (Contd..8) 76 Products under Development by Companies, H2 2014 (Contd..9) 77 Products under Development by Companies, H2 2014 (Contd..10) 78 Products under Development by Companies, H2 2014 (Contd..11) 79 Products under Development by Companies, H2 2014 (Contd..12) 80 Products under Development by Companies, H2 2014 (Contd..13) 81 Products under Development by Companies, H2 2014 (Contd..14) 82 Products under Development by Companies, H2 2014 (Contd..15) 83 Products under Development by Companies, H2 2014 (Contd..16) 84 Products under Investigation by Universities/Institutes, H2 2014 85 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 86 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 87 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 88 Parkinson's Disease - Pipeline by AbbVie Inc., H2 2014 89 Parkinson's Disease - Pipeline by AC Immune SA, H2 2014 90 Parkinson's Disease - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 91 Parkinson's Disease - Pipeline by Acelot, Inc., H2 2014 92 Parkinson's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 93 Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H2 2014 94 Parkinson's Disease - Pipeline by Advinus Therapeutics Ltd., H2 2014 95 Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 96 Parkinson's Disease - Pipeline by Affichem, H2 2014 97 Parkinson's Disease - Pipeline by AFFiRiS AG, H2 2014 98 Parkinson's Disease - Pipeline by Alexza Pharmaceuticals, Inc., H2 2014 99 Parkinson's Disease - Pipeline by Allergan, Inc., H2 2014 100 Parkinson's Disease - Pipeline by AlzProtect SAS, H2 2014 101 Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 102 Parkinson's Disease - Pipeline by American Gene Technologies International Inc., H2 2014 103 Parkinson's Disease - Pipeline by Amicus Therapeutics, Inc., H2 2014 104 Parkinson's Disease - Pipeline by Anavex Life Sciences Corp., H2 2014 105 Parkinson's Disease - Pipeline by AnGes MG, Inc., H2 2014 106 Parkinson's Disease - Pipeline by AngioChem Inc., H2 2014 107 Parkinson's Disease - Pipeline by Angita B.V., H2 2014 108 Parkinson's Disease - Pipeline by ApoPharma Inc., H2 2014 109 Parkinson's Disease - Pipeline by Aposense Ltd., H2 2014 110 Parkinson's Disease - Pipeline by Araclon Biotech, S.L., H2 2014 111 Parkinson's Disease - Pipeline by ArisGen SA, H2 2014 112 Parkinson's Disease - Pipeline by ArmaGen Technologies, Inc., H2 2014 113 Parkinson's Disease - Pipeline by Arrien Pharmaceuticals, LLC, H2 2014 114 Parkinson's Disease - Pipeline by Ascendis Pharma A/S, H2 2014 115 Parkinson's Disease - Pipeline by AstraZeneca PLC, H2 2014 116 Parkinson's Disease - Pipeline by Bial - Portela & Ca, S.A., H2 2014 117 Parkinson's Disease - Pipeline by BioArctic Neuroscience AB, H2 2014 118 Parkinson's Disease - Pipeline by Biogen Idec Inc., H2 2014 119 Parkinson's Disease - Pipeline by BioMarin Pharmaceutical Inc., H2 2014 120 Parkinson's Disease - Pipeline by Bionature E.A. Ltd., H2 2014 121 Parkinson's Disease - Pipeline by Bionure Farma, S.L., H2 2014 122 Parkinson's Disease - Pipeline by Biotie Therapies Corp., H2 2014 123 Parkinson's Disease - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2014 124 Parkinson's Disease - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014 125 Parkinson's Disease - Pipeline by Calico LLC, H2 2014 126 Parkinson's Disease - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 127 Parkinson's Disease - Pipeline by Cell Cure Neurosciences, Ltd., H2 2014 128 Parkinson's Disease - Pipeline by Cellceutix Corporation, H2 2014 129 Parkinson's Disease - Pipeline by CHA Bio & Diostech Co., Ltd., H2 2014 130 Parkinson's Disease - Pipeline by Chipscreen Biosciences Ltd, H2 2014 131 Parkinson's Disease - Pipeline by Chronos Therapeutics Limited, H2 2014 132 Parkinson's Disease - Pipeline by Civitas Therapeutics, Inc., H2 2014 133 Parkinson's Disease - Pipeline by Clera Inc., H2 2014 134 Parkinson's Disease - Pipeline by Contera Pharma ApS, H2 2014 135 Parkinson's Disease - Pipeline by Cortex Pharmaceuticals, Inc., H2 2014 136 Parkinson's Disease - Pipeline by CrystalGenomics, Inc., H2 2014 137 Parkinson's Disease - Pipeline by Curemark, LLC, H2 2014 138 Parkinson's Disease - Pipeline by Cynapsus Therapeutics Inc., H2 2014 139 Parkinson's Disease - Pipeline by D-Pharm Ltd., H2 2014 140 Parkinson's Disease - Pipeline by Depomed, Inc., H2 2014 141 Parkinson's Disease - Pipeline by Domain Therapeutics SA, H2 2014 142 Parkinson's Disease - Pipeline by Edison Pharmaceuticals, Inc., H2 2014 143 Parkinson's Disease - Pipeline by Eucalyptus Ltd., H2 2014 144 Parkinson's Disease - Pipeline by Euroscreen S.A., H2 2014 145 Parkinson's Disease - Pipeline by Gene Solutions LLC, H2 2014 146 Parkinson's Disease - Pipeline by Genentech, Inc., H2 2014 147 Parkinson's Disease - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 148 Parkinson's Disease - Pipeline by Genosco, H2 2014 149 Parkinson's Disease - Pipeline by GlaxoSmithKline plc, H2 2014 150 Parkinson's Disease - Pipeline by GliaCure Inc., H2 2014 151 Parkinson's Disease - Pipeline by H. Lundbeck A/S, H2 2014 152 Parkinson's Disease - Pipeline by Harbor Therapeutics, Inc., H2 2014 153 Parkinson's Disease - Pipeline by Herantis Pharma plc., H2 2014 154 Parkinson's Disease - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 155 Parkinson's Disease - Pipeline by Hua Medicine Ltd., H2 2014 156 Parkinson's Disease - Pipeline by Huons Co., Ltd., H2 2014 157 Parkinson's Disease - Pipeline by Intec Pharma ltd., H2 2014 158 Parkinson's Disease - Pipeline by Integrative Research Laboratories Sweden AB, H2 2014 159 Parkinson's Disease - Pipeline by InterMed Discovery GmbH, H2 2014 160 Parkinson's Disease - Pipeline by InterMune, Inc., H2 2014 161 Parkinson's Disease - Pipeline by International Stem Cell Corporation, H2 2014 162 Parkinson's Disease - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 163 Parkinson's Disease - Pipeline by Inventiva SAS, H2 2014 164 Parkinson's Disease - Pipeline by Io Therapeutics, Inc., H2 2014 165 Parkinson's Disease - Pipeline by Iproteos S.L., H2 2014 166 Parkinson's Disease - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2014 167 Parkinson's Disease - Pipeline by KineMed, Inc., H2 2014 168 Parkinson's Disease - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 169 Parkinson's Disease - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 170 Parkinson's Disease - Pipeline by Lead Discovery Center GmbH, H2 2014 171 Parkinson's Disease - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 172 Parkinson's Disease - Pipeline by Living Cell Technologies Limited, H2 2014 173 Parkinson's Disease - Pipeline by Longevity Biotech, Inc, H2 2014 174 Parkinson's Disease - Pipeline by Luye Pharma Group Ltd., H2 2014 175 Parkinson's Disease - Pipeline by M et P Pharma AG, H2 2014 176 Parkinson's Disease - Pipeline by Medeia Therapeutics Ltd., H2 2014 177 Parkinson's Disease - Pipeline by MedGenesis Therapeutix Inc., H2 2014 178 Parkinson's Disease - Pipeline by Merck & Co., Inc., H2 2014 179 Parkinson's Disease - Pipeline by Mesoblast Limited, H2 2014 180 Parkinson's Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2014 181 Parkinson's Disease - Pipeline by Minerva Neurosciences, Inc., H2 2014 182 Parkinson's Disease - Pipeline by MitoDys Therapeutics Ltd, H2 2014 183 Parkinson's Disease - Pipeline by Motac Neuroscience Ltd, H2 2014 184 Parkinson's Disease - Pipeline by Netherlands Translational Research Center B.V., H2 2014 185 Parkinson's Disease - Pipeline by Neuralstem, Inc., H2 2014 186 Parkinson's Disease - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2014 187 Parkinson's Disease - Pipeline by Neuren Pharmaceuticals Limited, H2 2014 188 Parkinson's Disease - Pipeline by NeuroDerm Ltd., H2 2014 189 Parkinson's Disease - Pipeline by Neurodyn Inc., H2 2014 190 Parkinson's Disease - Pipeline by Neurolixis Inc., H2 2014 191 Parkinson's Disease - Pipeline by NeuroNascent, Inc., H2 2014 192 Parkinson's Disease - Pipeline by NeuroPhage Pharmaceuticals, Inc., H2 2014 193 Parkinson's Disease - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 194 Parkinson's Disease - Pipeline by nLife Therapeutics, S.L., H2 2014 195 Parkinson's Disease - Pipeline by Novartis AG, H2 2014 196 Parkinson's Disease - Pipeline by NsGene A/S, H2 2014 197 Parkinson's Disease - Pipeline by Omeros Corporation, H2 2014 198 Parkinson's Disease - Pipeline by Oncodesign SA, H2 2014 199 Parkinson's Disease - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 200 Parkinson's Disease - Pipeline by OPKO Health, Inc., H2 2014 201 Parkinson's Disease - Pipeline by Orion Oyj, H2 2014 202 Parkinson's Disease - Pipeline by Oryzon Genomics S.A., H2 2014 203 Parkinson's Disease - Pipeline by Osmotica Pharmaceutical Corp., H2 2014 204 Parkinson's Disease - Pipeline by Oxford BioMedica plc, H2 2014 205 Parkinson's Disease - Pipeline by OXIS International, Inc. (Inactive), H2 2014 206 Parkinson's Disease - Pipeline by P2D Bioscience, H2 2014 207 Parkinson's Disease - Pipeline by Peptron, Inc., H2 2014 208 Parkinson's Disease - Pipeline by Pfizer Inc., H2 2014 209 Parkinson's Disease - Pipeline by Pharma Two B Ltd, H2 2014 210 Parkinson's Disease - Pipeline by Pharmicell Co., Ltd., H2 2014 211 Parkinson's Disease - Pipeline by Pharnext SAS, H2 2014 212 Parkinson's Disease - Pipeline by Prana Biotechnology Limited, H2 2014 213 Parkinson's Disease - Pipeline by Prexton Therapeutics SA, H2 2014 214 Parkinson's Disease - Pipeline by Promentis Pharmaceuticals, Inc., H2 2014 215 Parkinson's Disease - Pipeline by ProteoTech, Inc., H2 2014 216 Parkinson's Disease - Pipeline by Prothena Corporation plc, H2 2014 217 Parkinson's Disease - Pipeline by PsychoGenics, Inc., H2 2014 218 Parkinson's Disease - Pipeline by QR Pharma, Inc., H2 2014 219 Parkinson's Disease - Pipeline by QRxPharma Limited, H2 2014 220 Parkinson's Disease - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 221 Parkinson's Disease - Pipeline by Reliance Life Sciences Pvt. Ltd., H2 2014 222 Parkinson's Disease - Pipeline by reMYND, H2 2014 223 Parkinson's Disease - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 224 Parkinson's Disease - Pipeline by RhinoCyte, Inc., H2 2014 225 Parkinson's Disease - Pipeline by SanBio, Inc., H2 2014 226 Parkinson's Disease - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014 227 Parkinson's Disease - Pipeline by Sangamo BioSciences, Inc., H2 2014 228 Parkinson's Disease - Pipeline by Saniona AB, H2 2014 229 Parkinson's Disease - Pipeline by Sanofi, H2 2014 230 Parkinson's Disease - Pipeline by Sellas Inc., H2 2014 231 Parkinson's Disease - Pipeline by Selvita SA, H2 2014 232 Parkinson's Disease - Pipeline by Serina Therapeutics, Inc., H2 2014 233 Parkinson's Disease - Pipeline by Shire Plc, H2 2014 234 Parkinson's Disease - Pipeline by Sigma-Tau S.p.A., H2 2014 235 Parkinson's Disease - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 236 Parkinson's Disease - Pipeline by STATegics, Inc., H2 2014 237 Parkinson's Disease - Pipeline by Stelic Institute & Co., H2 2014 238 Parkinson's Disease - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 239 Parkinson's Disease - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 240 Parkinson's Disease - Pipeline by Targacept, Inc., H2 2014 241 Parkinson's Disease - Pipeline by TauRx Therapeutics Ltd., H2 2014 242 Parkinson's Disease - Pipeline by Tautatis Incorporated, H2 2014 243 Parkinson's Disease - Pipeline by TechnoPhage SA, H2 2014 244 Parkinson's Disease - Pipeline by tesa Labtec GmbH, H2 2014 245 Parkinson's Disease - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 246 Parkinson's Disease - Pipeline by Trevena, Inc., H2 2014 247 Parkinson's Disease - Pipeline by Treventis Corporation, H2 2014 248 Parkinson's Disease - Pipeline by UCB S.A., H2 2014 249 Parkinson's Disease - Pipeline by UniQure NV, H2 2014 250 Parkinson's Disease - Pipeline by Upsher-Smith Laboratories, Inc., H2 2014 251 Parkinson's Disease - Pipeline by Valens Therapeutics, Inc., H2 2014 252 Parkinson's Disease - Pipeline by Varinel, Inc., H2 2014 253 Parkinson's Disease - Pipeline by Vernalis plc, H2 2014 254 Parkinson's Disease - Pipeline by VistaGen Therapeutics , Inc., H2 2014 255 Parkinson's Disease - Pipeline by VivaCell Biotechnology Espana S.L., H2 2014 256 Parkinson's Disease - Pipeline by XenoPort, Inc., H2 2014 257 Parkinson's Disease - Pipeline by Zenobia Therapeutics, Inc., H2 2014 258 Assessment by Monotherapy Products, H2 2014 259 Assessment by Combination Products, H2 2014 260 Number of Products by Stage and Target, H2 2014 262 Number of Products by Stage and Mechanism of Action, H2 2014 268 Number of Products by Stage and Route of Administration, H2 2014 274 Number of Products by Stage and Molecule Type, H2 2014 276 Parkinson's Disease Therapeutics - Recent Pipeline Updates, H2 2014 636 Parkinson's Disease - Dormant Projects, H2 2014 721 Parkinson's Disease - Discontinued Products, H2 2014 728
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
